Sequencio Therapeutics Company Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., announced that the Society for Immunotherapy of Cancer (SITC) has selected two abstracts from Sequencio for poster presentation at its 41st Annual Meeting, taking place 4–8 November 2026 in Phoenix, Arizona. The studies evaluated key elements of Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework, according to the announcement shared via Media OutReach Newswire.
The first study, CKLS118, is a TROP2 circular RNA-LNP therapeutic cancer vaccine tested in combination with anti-PD-1 therapy in two TROP2-positive tumour models. The vaccine enhanced the anti-tumour activity of lower-dose anti-PD-1 treatment compared with corresponding monotherapies and significantly increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours, indicating greater local immune activation. In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% and 88.9% when combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, versus 28.9% and 68.6% with anti-PD-1 alone. The findings support further development of CKLS118 in combination with checkpoint inhibition and evaluation of a potential dose-sparing strategy.
The second study, CKLS202, is a dual-antigen vaccine co-targeting human PD-L1 and PRAME, designed to combine tumour-antigen targeting with PD-L1-directed immune modulation. In humanised models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In the efficacy model, vaccination achieved 65% tumour growth inhibition and was associated with increased tumour-infiltrating CD4+ cells (0.94% to 2.97%), more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift toward a more immune-active tumour environment. Vaccinated tumour-free mice were also protected against tumour rechallenge, supporting durable antigen-specific immunity.
Dr Melvin Toh, Vice President & Chief Scientific Officer of CK Life Sciences, said the two posters provide an opportunity to share new data from the lead cancer vaccine programmes with the international immuno-oncology community. He noted the findings provide preclinical evidence supporting the intended mechanisms of action and demonstrate how the programmes may generate and sustain anti-tumour immune responses. Dr Toh added that while the programmes take distinct approaches, both engage multiple elements of the PINT framework, and the findings may help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease.
The studies address two key challenges in cancer immunotherapy: helping the immune system recognise and attack cancer cells, and overcoming mechanisms tumours use to evade immune responses. They explore complementary strategies—combining a TROP2 circular RNA vaccine with checkpoint inhibition, and using a dual-antigen vaccine designed to both help the immune system recognise cancer cells and address immune suppression. The use of humanised preclinical models contributes to the Translate element by helping researchers assess how findings may be relevant to humans.
For readers, the announcement signals that Sequencio's vaccine candidates are progressing toward human clinical trials, with data suggesting potential to enhance checkpoint inhibitor efficacy and possibly reduce required doses. If validated in humans, these approaches could offer new options for durable immune-controlled remission, particularly in peri-operative settings. The presentations are scheduled for 6 November 2026.
